2021
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka J, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021, 137: 1353-1364. PMID: 32871584, PMCID: PMC8555417, DOI: 10.1182/blood.2020006464.Peer-Reviewed Original ResearchConceptsT-cell/histiocyte-rich large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaMalignant B cellsDiffuse large B-cell lymphomaClassic Hodgkin lymphomaPD-1B cellsImmune signaturesImmune escapePD-1/PD-L1 pathwayPD-L1/PDImmune escape pathwayPD-1 blockadeImmune cell infiltratesPD-L1 expressionRefractory hematologic malignanciesPD-L1 pathwayMulti-institutional cohortClinical responsePartial responseCell infiltrateComplete responsePD-L1Aggressive variant
2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal Of Clinical Oncology 2019, 37: 2786-2794. PMID: 31461377, PMCID: PMC9798913, DOI: 10.1200/jco.19.01021.Peer-Reviewed Original ResearchConceptsPhase II studyEndometrial cancerObjective responseII studyMismatch repair-deficient (dMMR) solid tumorsMore mismatch repair proteinsEnd pointData cutoff dateMMRd endometrial cancersPersistent endometrial cancerTissue-agnostic approvalCoprimary end pointsPD-L1 statusPrimary end pointProgression-free survivalPD-L1 expressionPD-L1 inhibitorsCohort of patientsImmune checkpoint blockadeMismatch repair deficientUnacceptable toxicityCheckpoint blockadePatient selectionPolymerase chain reactionImmunohistochemical loss